Afimetoran

Overview

Afimetoran is an immunomodulator and an antagonist of toll-like receptors 7 and 8. It is also is under investigation in clinical trial NCT04269356 (Study to Assess the Way the Body Absorbs, Distributes, Breaks Down and Eliminates Radioactive BMS-986256 in Healthy Male Participants).

Indication

No indication information available.

Associated Conditions

No associated conditions information available.

Clinical Trials

Title	Posted	Study ID	Phase	Status	Sponsor
A Study to Assess the Effect of Phenytoin on the Drug Levels of Afimetoran and the Effect of Afimetoran on the Drug Levels of Midazolam	2023/06/13	NCT05901714	Phase 1	Completed	Bristol-Myers Squibb
A Study to Assess the Effect of Famotidine on the Drug Levels of Afimetoran in Healthy Participants	2023/05/19	NCT05866627	Phase 1	Recruiting	Bristol-Myers Squibb
A Study to Determine the Effect of Famotidine on the Drug Levels of BMS-986256 in Healthy Participants	2021/06/28	NCT04941755	Phase 1	Completed	Bristol-Myers Squibb
A Study Evaluating the Efficacy and Safety of Afimetoran Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE)	2021/05/20	NCT04895696	Phase 2	Active, not recruiting	Bristol-Myers Squibb
A Study to Assess the Safety and Drug Levels of BMS-986256 in Participants With Active Cutaneous Lupus Erythematosus	2020/07/30	NCT04493541	Phase 1	Completed	Bristol-Myers Squibb
Study to Assess the Effect of Acid-reducing Agent Famotidine on the Drug Levels of BMS-986256 in Healthy Participants	2020/07/14	NCT04470778	Phase 1	Completed	Bristol-Myers Squibb
Study to Assess the Way the Body Absorbs, Distributes, Breaks Down and Eliminates Radioactive BMS-986256 in Healthy Male Participants	2020/02/13	NCT04269356	Phase 1	Completed	Bristol-Myers Squibb
Effects of BMS-986256 at Steady State on the Single Dose Pharmacokinetics of Mycophenolate Mofetil	2019/07/31	NCT04039373	Phase 1	Completed	Bristol-Myers Squibb
A Study Measuring the Effectiveness of BMS-986256 Combined With Oral Contraceptive in Healthy Female Participants	2019/07/11	NCT04016753	Phase 1	Completed	Bristol-Myers Squibb
A Study to Investigate the Effects of Itraconazole on the Pharmacokinetics of BMS-986256 in Healthy Participants	2019/05/15	NCT03950960	Phase 1	Completed	Bristol-Myers Squibb

FDA Drug Approvals

Approved Product	Manufacturer	NDC Code	Route	Strength	Effective Date
No FDA approvals found for this drug.

EMA Drug Approvals

Approved Product	Authorization Holder	Status	Issued Date
No EMA approvals found for this drug.

HSA Drug Approvals

Approved Product	Manufacturer	Approval Number	Dosage Form	Strength	Approval Date
No HSA approvals found for this drug.

NMPA Drug Approvals

Approved Product	Company	Approval Number	Drug Type	Dosage Form	Approval Date
No NMPA approvals found for this drug.

PPB Drug Approvals

Approved Product	Registration No.	Company	Licence No.	Strength	Registration Date
No PPB approvals found for this drug.

TGA Drug Approvals

Approved Product	ARTG ID	Sponsor	Registration Type	Status	Registration Date
No TGA approvals found for this drug.

AI-Powered Research

Premium Access